Circulating tumor cells in metastatic breast cancer: Ready for clinical practice?

Maggie Banys-Paluchowski; Donata Grimm; Achim Rody; Peter Paluchowski; Natalia Krawczyk

Circulating tumor cells in metastatic breast cancer: Ready for clinical practice?

Maggie Banys-Paluchowski^*, Donata Grimm, Achim Rody, Peter Paluchowski, Natalia Krawczyk

^*Corresponding author for this work

Abstract

Circulating tumor cells (CTCs) can be routinely detected in peripheral blood of patients with solid malignancies. In metastatic breast cancer, presence of 5 or more CTCs per 7.5 ml blood has been shown to predict poor clinical outcome with level I evidence. Further, persistently high CTC counts are associated with inadequate response to therapy. However, it is unclear which therapeutic strategy should be recommended for these patients, since switching to an alternative chemotherapy regimen has not proven beneficial in the SWOG0500 study. In the context of liquid biopsy based interventions, several research groups have explored targeted therapies with DETECT III trial results presented at the SABCS 2020 being the latest "breaking news" in this setting. In the present review, we present and comment on the current evidence regarding CTCbased diagnostics in patients with metastatic breast cancer.

Original language	English
Title of host publication	Advances in Medicine and Biology
Number of pages	17
Volume	180
Publisher	Nova Science Publishers, Inc.
Publication date	07.06.2021
Pages	193-209
ISBN (Print)	9781536197655
ISBN (Electronic)	9781536198072
Publication status	Published - 07.06.2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)
Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

2.22-21 Gynaecology and Obstetrics
2.22-14 Hematology, Oncology

Cite this

@inbook{a1a5ba8680c5442190db31d7809af6ff,

title = "Circulating tumor cells in metastatic breast cancer: Ready for clinical practice?",

abstract = "Circulating tumor cells (CTCs) can be routinely detected in peripheral blood of patients with solid malignancies. In metastatic breast cancer, presence of 5 or more CTCs per 7.5 ml blood has been shown to predict poor clinical outcome with level I evidence. Further, persistently high CTC counts are associated with inadequate response to therapy. However, it is unclear which therapeutic strategy should be recommended for these patients, since switching to an alternative chemotherapy regimen has not proven beneficial in the SWOG0500 study. In the context of liquid biopsy based interventions, several research groups have explored targeted therapies with DETECT III trial results presented at the SABCS 2020 being the latest {"}breaking news{"} in this setting. In the present review, we present and comment on the current evidence regarding CTCbased diagnostics in patients with metastatic breast cancer.",

author = "Maggie Banys-Paluchowski and Donata Grimm and Achim Rody and Peter Paluchowski and Natalia Krawczyk",

note = "Publisher Copyright: {\textcopyright} 2019 Nova Science Publishers, Inc.",

year = "2021",

month = jun,

day = "7",

language = "English",

isbn = "9781536197655",

volume = "180",

pages = "193--209",

booktitle = "Advances in Medicine and Biology",

publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Circulating tumor cells in metastatic breast cancer

T2 - Ready for clinical practice?

AU - Banys-Paluchowski, Maggie

AU - Grimm, Donata

AU - Rody, Achim

AU - Paluchowski, Peter

AU - Krawczyk, Natalia

PY - 2021/6/7

Y1 - 2021/6/7

N2 - Circulating tumor cells (CTCs) can be routinely detected in peripheral blood of patients with solid malignancies. In metastatic breast cancer, presence of 5 or more CTCs per 7.5 ml blood has been shown to predict poor clinical outcome with level I evidence. Further, persistently high CTC counts are associated with inadequate response to therapy. However, it is unclear which therapeutic strategy should be recommended for these patients, since switching to an alternative chemotherapy regimen has not proven beneficial in the SWOG0500 study. In the context of liquid biopsy based interventions, several research groups have explored targeted therapies with DETECT III trial results presented at the SABCS 2020 being the latest "breaking news" in this setting. In the present review, we present and comment on the current evidence regarding CTCbased diagnostics in patients with metastatic breast cancer.

AB - Circulating tumor cells (CTCs) can be routinely detected in peripheral blood of patients with solid malignancies. In metastatic breast cancer, presence of 5 or more CTCs per 7.5 ml blood has been shown to predict poor clinical outcome with level I evidence. Further, persistently high CTC counts are associated with inadequate response to therapy. However, it is unclear which therapeutic strategy should be recommended for these patients, since switching to an alternative chemotherapy regimen has not proven beneficial in the SWOG0500 study. In the context of liquid biopsy based interventions, several research groups have explored targeted therapies with DETECT III trial results presented at the SABCS 2020 being the latest "breaking news" in this setting. In the present review, we present and comment on the current evidence regarding CTCbased diagnostics in patients with metastatic breast cancer.

UR - https://www.scopus.com/pages/publications/85116518525

M3 - Chapter

AN - SCOPUS:85116518525

SN - 9781536197655

VL - 180

SP - 193

EP - 209

BT - Advances in Medicine and Biology

PB - Nova Science Publishers, Inc.

ER -

Circulating tumor cells in metastatic breast cancer: Ready for clinical practice?

Abstract

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Other files and links

Fingerprint

Cite this